Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Research Collaboration Agreement to initiate a vaccine program for the potential prevention of COVID-19 or other viral infections. This effort will augment Nascent’s current development plants to investigate the utility of Pritumumab for the treatment of COVID-19.
Lead Product(s): Recombinant Mycobacterium Bovis Bacillus Calmette-Guerin
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Nascent Biotech
Deal Size: $0.2 million Upfront Cash: $0.1 million
Deal Type: Collaboration May 12, 2020